A detailed history of Prudential Financial Inc transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Prudential Financial Inc holds 81,338 shares of PCVX stock, worth $8.59 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
81,338
Previous 54,841 48.32%
Holding current value
$8.59 Million
Previous $3.75 Million 63.93%
% of portfolio
0.01%
Previous 0.01%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$60.06 - $78.77 $1.59 Million - $2.09 Million
26,497 Added 48.32%
81,338 $6.14 Million
Q1 2024

May 14, 2024

BUY
$59.79 - $81.05 $1.1 Million - $1.49 Million
18,330 Added 50.2%
54,841 $3.75 Million
Q4 2023

Feb 13, 2024

BUY
$45.35 - $63.41 $11,020 - $15,408
243 Added 0.67%
36,511 $2.29 Million
Q3 2023

Nov 13, 2023

SELL
$46.0 - $53.1 $3.88 Million - $4.48 Million
-84,332 Reduced 69.93%
36,268 $1.85 Million
Q2 2023

Aug 11, 2023

BUY
$34.66 - $54.07 $2.72 Million - $4.24 Million
78,383 Added 185.67%
120,600 $6.02 Million
Q1 2023

May 12, 2023

BUY
$36.27 - $47.2 $30,938 - $40,261
853 Added 2.06%
42,217 $1.58 Million
Q4 2022

Feb 14, 2023

BUY
$20.58 - $47.95 $554,281 - $1.29 Million
26,933 Added 186.63%
41,364 $0
Q3 2022

Nov 04, 2022

BUY
$21.69 - $28.53 $5,747 - $7,560
265 Added 1.87%
14,431 $347,000
Q2 2022

Aug 15, 2022

BUY
$17.68 - $26.58 $250,454 - $376,532
14,166 New
14,166 $308,000
Q1 2022

May 13, 2022

SELL
$17.46 - $26.36 $173,203 - $261,491
-9,920 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$19.32 - $26.45 $191,654 - $262,384
9,920 New
9,920 $236,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $6.26B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.